Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma

Clinical Cancer Research, 04/12/2012

Systemic treatment with bevacizumab prior to regional chemotherapy increases delivery of melphalan (LPAM) to tumor cells and represents a novel way to augment response to regional therapy for advanced extremity melanoma.

Print Article Summary Cat 2 CME Report